Galapagos discovers novel class of antibiotics that kill all MRSA strains

11/27/2012 | Examiner.com

Belgian biotech firm Galapagos said it has identified a new class of antibiotics that demonstrate strong activity against drug-resistant strains of Staphylococcus aureus, including MRSA. The antibiotic acts against an enzyme that is key to the growth of all bacteria, the company said. Galapagos said clinical studies could begin for the antibiotic candidate CAM-1 in early 2014.

View Full Article in:

Examiner.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN